Biotech Startups

Eliem Therapeutics is a clinical-stage biotechnology company developing monoclonal antibodies targeting immune-mediated diseases, with budoprutug, an anti-CD19 antibody designed to deplete B cells in conditions including primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL antibody for IgA nephropathy and related B-cell mediated diseases.

1 investor

ELIGARD is a GnRH agonist medication in injectable form used to treat prostate cancer by reducing testosterone production. The product offers multiple dosing schedules for patients with metastatic castration-sensitive prostate cancer.

1 investor

EligoChem is a drug discovery company staffed by directors with expertise in medicinal and computational chemistry, biology assay development, and screening.

1 investor

Elisigen develops AAV-based gene therapies designed for durable, long-term therapeutic protein expression in vivo, aiming to reduce repeated dosing. Its pipeline targets conditions including vision loss (such as wet age-related macular degeneration) and chronic pain.

1 investor

ELITechGroup develops, manufactures, and markets in-vitro diagnostics products including instruments, reagents, and software for hospitals and diagnostic laboratories. Its work spans molecular diagnostics, biomedical systems, and microbiology, and it operates in over 100 countries as part of Bruker Corporation.

1 investor

Elle, MD is a female-founded biotechnology company developing Livv, a once-monthly, non-hormonal contraceptive ring that works locally in the reproductive tract to prevent fertilization. It aims to expand the device to include emergency contraception, creating a patient-controlled dual-indication contraceptive for women's reproductive health.

1 investor

Ellipses Pharma develops cancer treatments targeting unmet clinical needs across various cancer types and molecular mechanisms.

1 investor

Ellis Bio develops genomic and epigenetic analysis technologies for research and diagnostics, leveraging proprietary RNA and DNA methylation research. The company serves biotech and pharmaceutical organizations seeking advanced sequencing and detection capabilities.

1 investor

Elm Street Ventures is a seed and early-stage venture capital fund that invests in startups with a Yale University connection, typically commercializing research licensed from Yale, as well as companies in the greater New Haven area. Its portfolio spans therapeutics, industrial tools and materials, and climate-focused interventions.

1 investor

A contract manufacturer of probiotic products in various formulations including capsules, suspensions, and syrups for the Indian market since 2018.

1 investor

Elnora is an AI agent for laboratory research that plans experiments, writes protocols, searches scientific literature and patents, and analyses experimental results using a team's own protocols, data and notes. It serves life sciences researchers across biology, chemistry, materials, electrochemistry and physics, and is accessible via browser, a hosted MCP server, REST API or command line.

1 investor

Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical company developing small molecule therapeutics designed to address nonsense mutation genetic disorders. The company is advancing exaluren for rare kidney diseases including Alport syndrome and ADPKD through clinical trials.

1 investor

Elphogene develops oncoMonitor, a liquid biopsy molecular test that detects circulating tumor DNA (ctDNA) from patients' blood for non-invasive monitoring of cancer progression and treatment, primarily for colorectal cancer patients. The company is a biotechnology spin-off from the Genomac Research Institute.

1 investor

1 investor

Elut is a clinical-stage medical device company developing patented drug-eluting devices that provide controlled, sustained therapeutic release, with a current focus on treating orthopedic and periprosthetic joint infections. Its technology is applied to bone void fillers that deliver local antibiotics over an eight-week period.

1 investor

Elutia develops a proprietary drug-eluting biomaterial platform that combines biologic matrices with extended antibiotic release for use in device implantation and soft tissue reconstruction. Its allograft products serve surgeons performing reconstructive and cardiovascular repair procedures in the medical device and regenerative medicine field.

1 investor

Emalex Biosciences is a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders, with a lead investigational asset, ecopipam, a selective dopamine D1 receptor antagonist for pediatric Tourette syndrome. The company, created by Paragon Biosciences, advanced ecopipam through Phase 3 development and was acquired by Teva Pharmaceutical Industries in June 2026.

1 investor

Emblok develops the Emblok 360° whole body embolic protection system, a medical device used during left heart procedures such as TAVR to block and capture emboli and debris. It aims to reduce the risk of procedure-related strokes and damage to the heart, kidneys, and intestines for physicians and patients.

1 investor

Zimmer Biomet develops medical devices and orthopedic solutions for patients and healthcare providers globally. The company operates across more than 100 countries with a focus on advancing patient safety, quality, and diversity in healthcare innovation.

1 investor

Emerald Inno develops a contactless health monitoring device that uses radio wave analysis and machine learning to detect human movement and extract clinical health data without wearables or manual data synchronization. The platform serves clinical research and health studies with proprietary algorithms that process behavioral and movement data.

1 investor

Emerald BioAgriculture develops biology-based products and solutions using advanced biomanufacturing processes for plant, animal, and human health across various markets. The company specializes in biochemistry, microbials, enzymes, amino acids, peptides, and nutrients with integrated capabilities from discovery through manufacturing.

1 investor

Empirico is a clinical-stage biotechnology company that pairs human genetics-driven target discovery with siRNA medicine development to create genetic medicines for common diseases with unmet need. It runs an integrated drug discovery organization spanning computational target discovery, target validation, siRNA chemistry and clinical development.

1 investor

Empress provides drug discovery teams with an industrialized Perturb-seq platform that combines CRISPR-based single-cell functional genomics, chemoproteomics, and multi-omics with causal machine learning to identify what drives activity, efficacy, and risk. It serves pharmaceutical and biotech R&D teams seeking mechanistic understanding of drug targets.

1 investor

Emtora Biosciences is a clinical-stage life science company developing eRapa, a novel formulation of rapamycin, to prevent the onset and recurrence of cancer. Its lead program, Serenta (eRapa), is in a Phase 3 trial evaluating safety and efficacy in patients diagnosed with familial adenomatous polyposis (FAP).

1 investor